In Brief
Causal enhancer-target-gene relationships are inferred from a systematic analysis of 33 cancer types.
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INTRODUCTION
The biological functions of each cell component are controlled by a Russian-nesting-doll-like multi-level gene-regulatory hierarchy that includes transcription-factor-promoter interaction, enhancer activation, DNA methylation, microRNA-mediated regulation, translation, and post-translational modification (He and Hannon, 2004; Jaenisch and Bird, 2003; Murakawa et al., 2016) . In cancer cells, such regulatory networks are often rewired by molecular aberrations that collectively lead to the cancer phenotype (Chen et al., 2015; Kolch et al., 2015) . For example, somatic mutations can modify the functions of both trans and cis elements in a regulatory network, thereby conferring cell behaviors related to tumorigenesis (Garraway and Lander, 2013; Hanahan and Weinberg, 2011) . Using highthroughput molecular profiling techniques over large patient cohorts, The Cancer Genome Atlas (TCGA) (Cancer Genome Atlas Research Network et al., 2013) has systematically characterized key molecular alterations at different levels in a broad range of cancer types, providing unprecedented insight into oncogenic mechanisms and potential therapeutic approaches. However, our information on the rewiring of gene regulatory networks in cancer is far from complete, and enhancers represent a missing piece of the jigsaw puzzle (Aran and Hellman, 2013) . Enhancers are important non-coding DNA elements that interact spatially with their target promoters to regulate downstream genes (Schmitt et al., 2016) . As a major category of regulatory elements in cell development, enhancers also play critical roles in the oncogenic process (Murakawa et al., 2016) . Despite recent systematic efforts, including genome-wide profiling of tissue and cell line collections (ENCODE Project Consortium, 2012; Hnisz et al., 2013; Roadmap Epigenomics Consortium et al., 2015) and a pan-cancer analysis of some super-enhancers (Zhang et al., 2016) , a global view of enhancer activity in cancer is still lacking. That hole in our understanding is due in part to the technical difficulty of applying high-throughput techniques (e.g., ChIP-seq) to investigate enhancer activity using large patient sample cohorts.
The Functional Annotation of the Mammalian Genome (FANTOM) Project has generated large-scale, high-quality annotation of $65,000 enhancers expressed in the human genome across multiple tissues (Andersson et al., 2014) . FANTOM thus provides an alternative solution for studying enhancer activities in cancer. An inactive enhancer is usually well organized by unmodified nucleosomes, so it cannot be accessed by either transcription factors or polymerase. When an enhancer is primed for activation in response to signaling, its local chromatin is first modified (often by H3K4Me1) and becomes loose, rendering the motifs on the enhancer available to transcription factors and RNA polymerase. When the bound transcription factors fully activate the enhancer, usually with re-marked by H3K27Ac, the local chromatin is completely open, recruiting RNA polymerase to initiate transcription in both directions (Figure 1A ) (Heinz et al., 2015; Li et al., 2016; Murakawa et al., 2016 ). Thus, the expression level of enhancer RNA molecules represents an (E) Numbers of prognostic enhancers in different cancer types. For each enhancer, its correlation with patients' survival times in a given cancer type was calculated using Cox regression. The p value was subjected to multiple-testing correction, with FDR = 0.05 as cut-off. essential signature of enhancer activation (Murakawa et al., 2016; Ren, 2010) . Indeed, the expression of a substantial proportion of enhancers can be detected by RNA sequencing (RNAseq) (Andersson et al., 2014; De Santa et al., 2010; Djebali et al., 2012; Murakawa et al., 2016) . Using the high-quality expressed enhancer annotations in the FANTOM project, we performed a pan-cancer analysis of enhancer expression using TCGA RNA-seq data on the premise that the expression of an enhancer approximately reflects its activity. We aimed to achieve the following: (1) describe the global pattern of enhancer expression in cancers; (2) understand how enhancer activation relates to other genomic aberrations and to the relevant underlying mechanisms; and (3) identify key enhancers and explore their potential clinical implications.
RESULTS
Overview of Enhancer Expression in Human Cancers
An enhancer's expression level has been used as an index of its activity (Cheng et al., 2015; Natoli and Andrau, 2012) . The FANTOM Project annotated enhancers based on integration of chromatin modification, transcription factor binding, cap analysis of gene expression (CAGE)-seq data (Andersson et al., 2014) , and TCGA-generated gene-expression data using RNAseq. To ensure the quality of our analysis, we first assessed whether TCGA's RNA-seq platform could effectively capture the transcriptional signals from the FANTOM enhancers. Through a series of filters, we identified 15,808 detectable enhancers out of $65,000 FANTOM-annotated enhancers with a typical length of $200 bp that do not overlap with other known transcribed elements, thereby avoiding potential signal contamination ( Figure S1A , Table S1 , and STAR Methods). We examined the chromatin status of the flanking 1-kb sequences of those enhancers using several well-established factors, including DNase hypersensitivity, p300 binding, CTCF binding, H3K27Ac, and H3K4Me1 (Heintzman et al., 2007) . That analysis revealed chromatin signatures that are similar to those identified by classical enhancers but are in sharp contrast to those of the transcriptional start sites (TSSs) of protein-coding genes or lncRNAs. For example, H3K4Me1, a key marker that distinguishes enhancers from any other TSSs, was substantially enriched in our enhancer set but showed a clear depletion in the TSSs of protein-coding genes ( Figure 1B) . The observed chromatin signatures were not affected by genomic annotation (Figure S1B) . Those results confirm that our set consists principally of genuine enhancers rather than other transcribed units or transcriptional noise.
In the TCGA RNA-seq data on 8,928 cancer samples of 33 cancer types (Table S2) , we observed a substantial number of RNA-seq reads uniquely assigned to the 15,808 enhancers. Those mapped reads showed clear peaks centered on the enhancers identified (Figure 1C) . That clear pattern confirmed the biological significance of our cross-platform integration and distinguished the signals from transcriptional noise. Another potential issue in our analysis of enhancers arose from the relatively low depth of RNA-seq data . To evaluate the general utility of TCGA RNA-seq data for enhancer expression, we determined the numbers of enhancers with detectable expression in different cancer types. On average, 4,591 enhancers were detected in > 10% of the samples in a given cancer type, suggesting that enhancer expression signals detected contain considerable sampling power to represent cancer enhancer functions on a global scale ( Figure 1D and Table S3 ). To evaluate further the clinical significance of the enhancer expression, we assessed correlations of the expression levels with patient survival in each of the 25 cancer types that had sufficient sample size and follow-up time. That analysis identified a few dozen to thousands of prognostic enhancers per cancer type, and some of them tended to correlate with prognosis across multiple cancer types (Figures 1E, S1C, and S1D and Tables S1 and S4) . Given the same sample cohorts and FDR cutoff = 0.05, we compared the proportions of enhancers and protein-coding genes that showed prognostic significance. Interestingly, in most cancer types, the fraction of enhancers with prognostic power was comparable to, or even higher than, that of proteincoding genes ( Figure 1F ). Finally, we examined the variation in enhancer expression across cancer types based on global enhancer expression level (summarizing over all of the enhancers surveyed, in reads per million mapped reads [RPM] ). Liver hepatocellular carcinoma (LIHC) showed the lowest global enhancer expression level ($100 RPM), and thymoma (THYM) showed the highest ($240 RPM). Within each cancer type, there was also large variation (as large as $5-fold) among patient samples (Figure 1G) . Compared with adjacent normal tissues from the same patients, most cancer types showed global enhancer activation (paired t test, p < 0.05, for 13 cancer types that had > 10 matched tumor-normal pairs, Figure 1H ). Collectively, those results present a general picture of enhancer expression in human cancers and suggest that enhancer expression signals detected from TCGA RNA-seq data represent a biological dimension of interest, complementary to other genomic features. The enhancer expression datasets presented here provide a starting point for exploration by the research community.
Global Enhancer Activation in Cancer Is Positively Associated with Tumor Aneuploidy
Somatic copy-number alteration (SCNA) and point mutation are the two most common types of mutational events that impact the stability of a cancer genome. To explore the relationship between genomic instability and enhancer expression in cancer, we determined the correlations of global enhancer expression level (RPM) with the SCNA and mutation burdens in each cancer (Figure 2A ). In contrast, point mutations showed no correlation or a slight negative correlation ( Figure 2B ). These results indicate complex relationships between enhancer activation and different types of genomic aberrations in cancer.
To explore further the global patterns of enhancer expression across cancer types, we performed consensus clustering of tumor samples using the 1,500 ($10% of 15,808) enhancers with the highest coefficients of variation (CV) across samples (STAR Methods). Enhancer expression levels were Z-normalized within each cancer type to minimize tissue effects. The analysis resulted in three robust subtypes (clusters): C1, C2, and C3 were separated in the space of the top three principal components, and the clusters were not driven by disease type ( Figures 2C,  2D , and S2). Comparison of the enhancer-based subtypes with well-established pathological subtypes further supported the biological significance of the clustering ( Figures S3A and S3B ). The most distinct feature among the subtypes was their differential levels of global enhancer expression: the enhancer expression levels of the three subtypes were higher than those of their normal counterparts; subtype C2 showed the highest level of enhancer activation, 1.25-or 1.15-fold higher than that of normal or C1 and C3 samples ( Figure 2E) . Notably, the 15% increase of global enhancer expression was a large effect, indicating > 400 more activated enhancers in C2 than in C1 and C3 samples, up to be $30% of the active enhancers that a tumor usually has (Figure 2F) . Consistent with the associations between aneuploidy and global enhancer expression within individual cancer types, $25% of a typical C2 genome was affected by aneuploidy, 1.5-fold more than that of a typical C1 (16%) or C3 (15%) genome (Figure 2G) , indicating thousands more genes perturbed by SCNAs. In terms of mutation burden, subtype C1 samples contained slightly more point mutations than subtype C2, and both C1 and C2 showed significantly higher mutation burdens than subtype C3 ( Figure 2H ). We also saw that some cancer driver genes appeared to be under strong positive selection in subtype C1 ( Figures S3C and S3D ). For example, C1 had a 1.5-fold higher TP53 truncation rate than did the others. The decoupling of point mutations and global enhancer activation in the above pan-cancer analysis is compatible with the patterns we observed within cancer types (Figures 2A and 2B ). Taken together, the correlations of enhancer activation with genomic instability can be summarized as a tree ( Figure 2I ): subtype C1 was enriched with samples having high mutation load and low aneuploidy; subtype C2 was enriched with samples having high mutation load and high aneuploidy; and C3 was ''normallike,'' with low mutation load and low aneuploidy. Both the analyses within cancer types and the analyses across cancer types indicate that SCNAs, but not point mutations, are positively associated with enhancer activation.
A ''Chromatin-State''-Centered Model for the Interplay of Enhancer Activation, SCNAs, and Point Mutations The above section raised a question of great interest: why do SCNAs and point mutations correlate with global enhancer activation in cancer differently (or even, to some extent, inversely in some cancer types)? Variations in chromatin organization of the human genome have been reported to be major determinants of the variation of somatic mutation rates across the genome (Schuster-Bö ckler and Lehner, 2012); low mutation rate is a feature of open DNA because of their accessibility by the DNA repair machineries ( Figure 3A ) (Polak et al., 2014) . Interestingly, chromatin opening happens to be a prerequisite for enhancer activity ( Figure 1A ). Upon activation, enhancers loop to, and interact with, their target DNAs, creating topological DNA-DNA interactions ( Figure 3A ). Meanwhile, long-range DNA-DNA contacts physically increase the chance for loci far apart on the 1D-sequence to meet and rearrange with each other when breaks occur, generating structural alterations ( Figure 3A ) (Fudenberg et al., 2011) . Those observations collectively suggest a molecular mechanism in which SCNAs and point mutations are differently associated with global enhancer activation patterns established through differences in the openness of chromatin. In that model, compact chromatin favors point mutation and keeps enhancers silent; once chromatin opens, enhancers are more likely to be activated. Meanwhile, because unfolded DNA is elongated by one to two orders of magnitudes, longrange DNA-DNA interactions are more likely to occur, which increases the chance of DNA rearrangements (SCNAs). To test that hypothetical model further, we used SCNA and mutation data from whole-genome sequencing to perform the analysis across different genomic regions, thereby providing evidence independent of that from our cross-sample analyses (Figure 3B and STAR Methods) . A direct prediction of the model is that loose and compact chromatin regions in the cancer genome are dominated by SCNAs and mutations, respectively. Consistent with that prediction, in the cross-genomic-region analysis (using 1 Mb as a unit), DNA regions that featured markers of open chromatin (DNA hypersensitivity and H3K27Ac) were associated with higher rates of DNA doublestrand breaks (DBSs) and lower mutation rates. Also, as predicted, the relationship between chromatin state and enhancer expression was the same as that for chromatin state and DSBs. In contrast, closed chromatin, characterized by histone methylation (H3K9Me2 and H3K9Me3), displayed a strikingly Enhancer activation level was defined as the mean RPKM of all enhancer regions within a fragment. The mutation rate and DNA double-strand break rate were calculated for each fragment using whole-genome data from COSMIC (STAR Methods). DNase hypersensitivity and histone-modifications were obtained from the ENCODE ChIP-seq dataset, and the density of DNA-DNA interactions was determined using Hi-C data (STAR Methods). Spearman's correlation coefficients between genomic features were plotted as indicated. All correlations were of strong statistical significance (p < 10 À16 ).
(C) The top 500 10-kb human genome fragments with the highest breakpoint rates were considered as DSB hotspots, of which 204 and 296, respectively, were found inside and outside of the anchors of DNA loops detected by Hi-C. opposite pattern ( Figure 3B ). We also observed a significantly negative association between point mutations and enhancer activation across genomic regions (rho = À0.46, n = 2663, p < 10 À16 ). That correlation was much stronger than those in cross-sample comparisons (only 4 out of 25 cancer types showed significant negative correlations; Figure 2B ). Those differences are probably due to genome-wide SCNA and mutation burdens positively correlated across tumor samples of different disease stages ( Figure S4 ). Further, according to the model posited here, the long-range DNA-DNA interactions (Hi-C interactions) in open chromatin should at least partially explain the coincidence of enhancer activation and SCNAs across different genomic regions. To test that possibility, we examined the 500 10-kb fragments of the human genome with the highest DSB rates. We found that $40% (n = 204) of them overlapped with anchors of Hi-C loops, representing a > 3-fold enrichment (p < 10 À3 , permutation test, Figure 3C ). The same anchor regions also tended to overlap with the enhancers in our study (n = 15808; enrichment = 1.9-fold, p < 10 À3 ; permutation test, Figure 3D ). As summarized in Figure 3E , this hypothetical model provides a simple and reasonable, although tentative, explanation for differential associations of enhancer activation with SCNAs and with mutations.
Systematic Identification of Causal Enhancer-Cancer Gene Interactions
To elucidate the molecular functions of individual enhancers in cancer development and assess their clinical utility, it is important to identify their downstream target genes. Although new technologies like Hi-C (Jin et al., 2013) have been used to infer enhancer-gene interactions at the level of chromatin blocks (Dekker et al., 2013) , computational methods that can accurately pinpoint target genes are seriously needed. Integrating enhancer and mRNA expression data, we can obtain candidate target genes of an enhancer through co-expression analysis. For a given enhancer-gene combination that is co-expressed, there are at least three possible relationship models: (1) a causal relationship, in which changes in the expression of the enhancer cause differential expression of the gene; (2) a reactive relationship, in which the gene is upstream of the enhancer; and (3) a co-responsive relationship, in which the enhancer and the gene are both responding to other molecular changes (Figure 4A) . To distinguish the first (causal) model from the other two, we introduced expression quantitative trait loci (eQTL) information. The rationale was as follows: in the causal model, but not the other two, a single-nucleotide polymorphism (SNP) that affects the enhancer's activity would also affect expression of the enhancer's downstream target gene, thereby making the SNP (or a nearby, genetically linked SNP) an eQTL of the gene of interest. Finally, for such enhancer-gene pairs, we can use recently available Hi-C data to assess whether the imputed causal relationship is (or is not) likely to be direct regulation. Following the logic above, we developed a computational method to identify potential causal and direct enhancer-gene regulations ( Figure 4B ). First, we selected enhancers with at least one nearby (< 500 bp) common SNP annotated in the 1000 Genomes Project (minor allele frequency > 20%) or GTEx database (1000 Genomes Project Consortium et al., Lappalainen et al., 2013) . We focused on a set of 822 cancer genes that combined clinically actionable genes (i.e., biomarkers or therapeutic targets) (n = 126), OncoKB (n = 476), and the Cancer Gene Consensus (CGC, n = 567) (Chakravarty et al., 2017; Futreal et al., 2004; Yuan et al., 2016) . Second, we performed a coexpression analysis, which revealed $40,000 associations between the enhancers and the genes in R 4 of 33 TCGA cancer types (absolute Spearman's rho > 0.3 and FDR < 10 À4 ; STAR Methods). Third, we inferred casual relationships by examining whether the SNP on a given enhancer was an eQTL of the co-expressed gene in either the 1000 Genomes or the GTEx dataset. We then integrated the long-range DNA-DNA interaction data from Hi-C (Rao et al., 2014) to predict whether causal relationships were acting through direct enhancer-gene contacts or through regulatory cascades. Specifically, if an enhancer and its co-expressed gene were located in one of the two anchors of a Hi-C DNA loop, the pair were considered as possible instances of direct regulation if the signal in the eQTL analysis was significant (p < 0.05). For enhancer-gene co-expression pairs without detected Hi-C interactions, we set a more stringent eQTL cutoff at (FDR < 10 À4 , with multiple comparison correction to account for all SNPs of a given enhancer) and considered them as instances of casual regulation.
Using that approach, we identified 65 such interactions involving 49 enhancers and 47 cancer genes, resulting in a predicted enhancer-gene regulatory network ( Figure 4C ). In total, 22 and 8 of the cancer genes were annotated, respectively, as oncogenes and tumor suppressor genes (TSG) in CGC, indicating a trend toward oncogene regulations (background Oncogenes: TSGs = 214: 198 in CGC, p = 0.037, chi-square test, Figure 4C) . Those 30 genes are involved in diverse cancer hallmarks with bias toward proliferation and metastasis, according to CGC annotations ( Figure 4D ). Interestingly, consistent with the bias toward oncogenes and the previously observed global enhancer activation, our network is strongly enriched with positive regulations, 43 of 54 (80%) and 11 of 11 (100%) for causal regulations and direct causal regulations, respectively (p < 0.01 for both enrichments, Figure 4E ). Those results provide insight into the way in which global enhancer activation may contribute to tumor progression. They also identify individual enhancer-gene regulations that may be crucial in cancer development or clinical management.
Enhancers of Actionable Genes Show Potential Clinical Relevance
To investigate regulation by the enhancers identified as described above, we analyzed in detail an enhancer on chr22 (chr22:50980817À50981280, henceforth called enhancer 22) and its inferred target SYK. The ENCODE ChIP-seq dataset annotates a large number of protein-DNA interaction peaks within or flanking the enhancer 22 region (Figure 5A ), suggesting its role as a hub in a regulatory network. Three genetically linked SNPs are located in the enhancer, all of which are SYK eQTLs. For example, the T-allele of SNP rs5770772 was associated with higher expression of both enhancer 22 and SYK than the C-allele in the 1000 Genomes Project RNA-seq dataset ( Figures  5B and 5C ). When we analyzed the TCGA protein expression dataset, we confirmed that higher enhancer activity was associated with higher SYK protein levels ( Figures 5D and 5E ). SYK is an oncogenic driver that is activated in multiple types of late-stage cancer and is associated with poor clinical outcome (Puissant et al., 2014; Yu et al., 2015) . Consistent with that relationship, our own analysis of patient survival times further supported the role of enhancer 22 as a marker of poor prognosis in several cancer types ( Figures 5F-5K and S5 ). Since the eQTL, RNA-seq, and protein data were generated from independent platforms and the correlations were observed across multiple tissues of origin, these results provide evidence that enhancer 22 is a prognostic marker, largely through its effect on the downstream gene SYK.
Besides prognostic markers, enhancers may serve as predictive markers for therapeutic response. PD-L1 plays a key role in a cancer's escape from attack by the immune system and thus has been a major target of ''check-point inhibition'' immunotherapy, most prominently for lung cancer and melanoma (Topalian et al., 2016) . In our enhancer-gene regulation network, we found an enhancer (chr9:5580709-5581016, hereafter called enhancer 9) located $140kb from PD-L1. We observed strong co-expression between the PD-L1 mRNA level and the enhancer expression in multiple cancer types ( Figure 6A ). We then validated the coexpression in a cohort of 130 lung cancer cell lines from the Cancer Cell Line Encyclopedia database ( Figure 6B ). A PD-L1 eQTL close to the enhancer suggests the enhancer as an upstream regulator ( Figure 6C ). The Hi-C dataset from a panel of seven human cell lines further confirmed a direct interaction between the PD-L1 gene and the enhancer (Figures 6D and S6A) . Interestingly, out of the 161 transcription factors surveyed in the ENCODE project, NF-kB (measured with RELA/p65 ChIP-seq data) was the only one annotated for enhancer 9. Consistently, ChIP-seq data showed a strong NF-kB binding signal on the enhancer 9 and on the p65 binding motif of PD-L1's promoter ( Figure 6E ), strongly suggesting that NF-kB complex is involved in the enhancer/PD-L1 interaction. Consistent with that idea, the NF-kB dimer has recently been reported to be essential to PD-L1 activation (Gowrishankar et al., 2015) . To validate the causal effects of enhancer 9 on PD-L1 expression, we designed three pairs of single-guide CRISPR/Cas9 RNAs (sgRNAs) to delete enhancer 9. Using the most effective sgRNA pair, we obtained a stable lung cancer A549 cell line with the homozygous enhancer 9 deletion ( Figures 6F, S6B , and STAR Methods). As predicted, knockout of enhancer 9 substantially reduced PD-L1 expression ($10-fold) at both mRNA and protein levels (Figures 6G and 6H ) and largely masked the inductive effect ($80% reduction) of IFN-g (activating NF-kB) on PD-L1 expression ( Figures 6H and S6C) . Collectively, these results suggest an NF-kB-mediated enhancer-promoter interaction model of PD-L1 activation ( Figure 6I ). This example highlights the potentially important way in which enhancers can modulate key therapeutic targets.
DISCUSSION
Although the role of enhancers in cancer development has increasingly been recognized, genome-wide profiling studies on enhancer activity using conventional techniques (e.g., ChIP-seq) over large patient sample cohorts have not been done. Using TCGA RNA-seq data, we characterized the enhancer expression landscape in a broad range of cancer types. We observed global enhancer activation positively associated with large SCNAs, but not point mutations, and proposed a model in which chromatin state is a key contributor to the observed genomic patterns. In contrast to closed chromatin, which favors point mutations (Polak et al., 2014) , open DNA promotes structural rearrangements through long-range DNA-DNA interaction and activates enhancers by exposing them to transcription factors. The model provides insights into mutational landscape and clonal evolution. Epigenetic status, including histone modifications, nucleosome packaging, and DNA methylation, could be precisely inherited during cell division (Probst et al., 2009) . Variations in chromatin organization in a single tumor progenitor cell could, therefore, create striking differences among tumors if their effects are accumulated for many generations of cell growth. Chromatin organization could be substantially remodeled by histone gene mutations, which are frequently seen in cancers (Yuen and Knoepfler, 2013) , or by chromatin remodeling events such as SMURF2 or HMGB1 loss of function (Blank et al., 2012; Celona et al., 2011 ) that globally loosen the structure of the genome (Schwab, 2009) . Such events could create high cross-patient diversity of chromatin organization that may have crucial effects on genomic features such as SCNAs, point mutations, and enhancer activation. Thus, chromatin state could substantially shape the mutational landscape and at least partially explain an interesting, but incompletely understood, observation that tumors tend to be driven by either mutation (M class) or copy-number alteration (C class) (Ciriello et al., 2013) . Due to the polyA selection and relatively low depth of TCGA RNA-seq data, our analysis only covered a proportion of enhancers in the human genome and may contain some noise. Therefore, further efforts using alternative technologies would be required to achieve a more comprehensive picture of enhancer activity in human cancers. 
(legend continued on next page)
The global enhancer activation we observed in cancer samples (relative to those from normal issues, as shown in Figures  1H and 2E ) also provides insights into the clonal evolution of tumors. In contrast with microRNAs, which are dominantly downregulated in cancer (Lu et al., 2005) , enhancers are globally activated. Those up-and downregulations both serve to upregulate a large number of protein-coding genes, raising the question of their selective advantages. They may be a handy solution to stress in the short term of cancer evolution (Yona et al., 2012) , in which activation of oncogenes and loss of TSGs are favored. However, given the nature of mutations, loss-of-function mutations are much easier to obtain than gain-of-function (activating) ones. As a result, cells with global gene activation could benefit from the advantages of oncogene activation. Meanwhile, the hitchhiked TSGs would be inactivated by loss-of-function mutations, which are more easily generated. Such an alternative may be particularly favored in cancer evolution (Yona et al., 2012) .
The co-expression-based enhancer-gene regulatory network we infer here is of high value from the perspectives of both systems and translational research. ChIP-seq and CAGE-seq have proven to be powerful techniques for searching enhancers (Andersson et al., 2014; Park, 2009) . A DNA-DNA interaction-based technique, Hi-C, has identified many enhancer-gene interactions (Schmitt et al., 2016) . However, these interactions have limitations: (1) no regulatory relationship behind the interaction is guaranteed; and (2) usually, only low-resolution interactions are available. For example, a typical Hi-C result generates interactions at a resolution level of 10-50 kb, whereas a typical enhancer is only $200 bp in length (Schmitt et al., 2016) . Therefore, the method we propose, based on co-expression, eQTL, and Hi-C data integration, may be complementary to the other approaches. Due to limited data from matched tissues across different datasets, we combined signals from different tissues in our pipeline to infer causal enhancer regulations, which may lead to some false positives. Independent experiments are required to validate the proposed enhancer regulations. Our analysis reveals a considerable number of enhancers, including enhancer 9 for PD-L1, that are associated with clinically actionable genes, including the experimentally validated regulation of enhancer 9 for PD-L1. These results suggest a conceptually alternative strategy to inhibit key therapeutic targets, and further efforts are required to investigate the potential of enhancers in clinical applications.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
HEK (human embryonic kidney) 293T was obtained from the MD Anderson Characterized Cell Line Core Facility. HEK293FT and A549 cell lines were purchased from American Type Culture Collection (ATCC). HEK293T and HEK293FT cells were cultured in Dulbecco's modification of Eagle's medium (DMEM) with 10% fetal bovine serum (Invitrogen) at 37 C and 5% CO 2 . A549, A549-cas9, and the cell lines established based on A549-cas9 were maintained in RPMI-1640 with 10% fetal bovine serum at 37 C and 5% CO 2 . The mycoplasma testing was confirmed to be negative for all the cell lines used in this study.
METHOD DETAILS
Annotation of expressed enhancers in TCGA RNA-seq data We obtained the information for 65423 FANTOM enhancers (Andersson et al., 2014) from http://fantom.gsc.riken.jp/5/datafiles/ latest/extra/Enhancers/human_permissive_enhancers_phase_1_and_2.bed.gz. For enhancer expression analysis, we first re-annotated the 65423 FANTOM enhancers according to the University of California, Santa Cruz gene annotation file (refgene.txt), FANTOM transcription start sites and alternative polyadenylation sites (Andersson et al., 2014) . We removed those that overlapped with known genes or intron regions, resulting in a subset of 15808 enhancers for which we could confidently assign the RNA-seq reads (Table S1) . As a further layer of quality control, we extended the definition of known transcription events to all Ensembl transcripts (v90) and identified 3228 out of 15808 enhancers overlapped with at least one Ensembl transcript (Table S1 ). All annotations were based on the human genome build hg19. We obtained 8928 TCGA RNA-seq BAM files of 33 cancer types from CGHub or the NCI Genomic Data Commons Data Portal. All these files were based on hg19 and processed by the TCGA genomic data analysis center at the University of North Carolina.
Chromatin state analysis of enhancers
We obtained all experimental data of DNase hypersensitivity, p300 binding, CTCF binding, H3K4Me1, and H3K27Ac modification from the ENCODE data portal (https://www.encodeproject.org/matrix/?type=Experiment). All files meeting the following criteria were included in the analysis: (1) Format = BigWig; (2) Genome version = Hg19; (3) Signal type = fold-change over control. The ChIP signal of an interested DNA region was extracted from BigWig files using UCSC software bigWigAverageOverBed. We then chose the output column ''mean'' to represent the signal intensity. ChIP signals were measured on the whole length of DNA or flanking 25 bp for enhancers or TSSs, respectively. The TSSs loci were obtained from UCSC (refgene.txt). For any element of interest, we also obtained the signal on its flanking 1kb regions (window size: 50 bp; step size: 50 bp). The 41 data points (50 bp 3 20 on up-stream sequence, 50 bp 3 20 on down-stream sequence, and one of the elements of interest, itself) were normalized as Z-scores. We then calculated the mean signal across all aligned sequences in all cell lines to generate the chromatin status plots in Figure 1B and Figure S1B . To further confirm the quality of our enhancer set, we compared them with all transcripts annotated by Ensembl, which was more comprehensive but also noisier. We identified 3228 out of 15808 ($20%) enhancers overlapping with at least one Ensembl transcript, but detected no differences on chromatin status between the two groups of enhancers; thus, we retained the 3228 enhancers for further analysis.
For the genomic-region-based analysis, we first obtained a human genome benchmark from ftp://ftp-trace.ncbi.nih.gov/giab/ ftp/data/NA12878/analysis/NIST_union_callsets_06172013/union13callableMQonlymerged_addcert_nouncert_excludesimplerep_ excludesegdups_excludedecoy_excludeRepSeqSTRs_noCNVs_v2.18_2mindatasets_5minYesNoRatio.bed.gz, which excluded the genomic regions that were ambiguous for mutation calling. We divided the human genome into 1Mb-sized fragments and only retained 2663 fragments with > 50kb (5% of 1Mb) benchmark sequences. The ChIP signal of each fragment was measured as described above except that only benchmark sequences were considered. For Hi-C data, we obtained the DNA-DNA interaction loops from the NCBI Gene Expression Omnibus (GEO) database (GEO: GSE63525) (Rao et al., 2014) . For breakpoint and mutation data analysis, we downloaded the files CosmicGenomeScreensMutantExport.tsv.gz and CosmicNCV.tsv.gz from COSMIC FTP and retained only the data annotated as ''WGS'' (whole genome sequencing) in both files. The mutation rate and breakpoint rate were calculated in the benchmark regions on each 1Mb-sized fragment. For the double strand break (DSB) hotspots, we divided the human genome into 10kb-sized fragments, calculated the DSB rate in the same way as for the 1Mb-sized fragments, and defined the top 500 fragments as DSB hotspots in the human genome, with a minimal DSB rate of 1.6 breakpoints per kb.
Comparison of global enhancer activation between tumor and normal samples
For the tumor versus normal tissue comparison, we considered a total of 13 cancer types with > 10 tumor-normal sample pairs. For each sample, we measured its global enhancer expression level by counting the number of reads per million mapped reads [RPM] on the surveyed enhancers (n = 15808). The y axis of Figure 1H was defined as (RPM Tumor /RPM Normal -1)%, where RPM Tumor (or RPM Normal ) was the mean RPM cross all tumor (or normal) samples of a given cancer type. Statistics were performed using paired t test.
Consensus clustering of enhancer expression profile
We calculated the log 2 RPKM values of the enhancers in TCGA samples as previously described (Li et al., 2015) . We excluded 599 samples with a low sequence depth to reduce noise and included 8329 samples in the clustering analysis. Within each of the 33 cancer types, we scaled the expression level (log 2 RPKM) of each enhancer into a Z-score. The Z-scores across all samples of 33 cancer types were combined to calculate the CV. The 10% (1,500 of 15808) of the enhancers with the highest CVs were subjected to consensus clustering using the R package ''ConsensusClusterPlus.'' When the number of clusters (k) increased from 2 to 10, we observed little gain of area under the cumulative distribution function curve in consensus clustering after k = 3 (Figure S2B ), which indicated that three clusters were identified in our analysis (Monti et al., 2003) .
Integrative analysis of enhancer expression with other molecular and clinical data For genomic variations, the SCNA level of each tumor was obtained from the cBioportal feature ''fraction of copy number altered genome,'' while mutations (TCGA PanCanAtlas MC3) were obtained from the NCI Genomic Data Commons Data Portal. We used the number of silent mutations per exome to quantify the overall mutation load since non-silent mutations could be largely affected by positive selection. These statistics were obtained by using the Kruskal-Wallis test. Subtype information was obtained from the TCGA PanCanAtlas Pathway Analysis Working Group. The chi-square test was used to test the independence of the subtype and enhancer cluster. For prognostic analysis, we first filtered the enhancers without detectable expression in > 10% of the samples in each cancer type. For each of the remaining enhancers, we used the Cox regression model and log-rank test to determine the enhancer's prognostic power. Enhancers associated with either the overall survival time or progression-free interval time (FDR < 0.05, John Storey's correction, Table S4 ) were considered as prognostic enhancers.
Inference of causal enhancer-gene regulation
We first constructed a cancer-type-specific enhancer-gene co-expression network. Enhancers with common SNPs (minor allele frequency > 0.2) in the 1000 Genomes Project dataset (1000 Genomes Project Consortium et al., 2012 or GTEx dataset or within their flanking 500 bp sequences were considered in this analysis. We combined a group of actionable genes (n = 126), OncoKB with the Cancer Gene Consensus (n = 567) to be the cancer gene set in the analysis. In each cancer type, we used Spearman's rank correlation model with Bonferroni's correction for multiple comparisons to determine the enhancer-gene co-expression. Co-expression of an enhancer-gene pair was defined as significant co-expressions (absolute Spearman's rho > 0.3 and FDR < 10 À4 ) in at least four cancer types (> 10% of the 33 cancer types). For each enhancer-gene co-expression pair, we then examined whether they contacted each other directly through long-range DNA-DNA loops. If they were located respectively on the two anchors on any DNA loops identified in NCBI GEO: GSE63525 (Rao et al., 2014) , we considered the co-expression as a potential direct regulation, for which, we then tested if the SNP on this enhancer was an eQTL of the paired gene (p < 0.05). For other co-expression pairs without detected interaction through DNA loops, we applied a more stringent cutoff (FDR < 10
À4
) for the eQTL analysis. For both direct and indirect regulations, the p values in eQTL tests were corrected according to the number of SNPs associated with each enhancer. The RNA-seq and genotype data of the 1000 Genomes Project and GTEx were obtained from http://www.internationalgenome.org/ category/rnaseq/ and dbGAP (phg000520), respectively (Lappalainen et al., 2013) . For the GTEx dataset, 11 tissues with R 80 samples were subjected to analysis: adipose_tissue, blood, blood_vessel, brain, esophagus, heart, lung, muscle, nerve, skin, and thyroid. For the eQTL analysis, we first artificially assigned the genotype scores of 1, 2, and 3 to individuals with genotypes of 0/0, 0/1, and 1/1, respectively. Spearman's correlation between the genotype score and the gene's expression was used to determine if the SNP was an eQTL of the gene. If more than one SNP was associated with an enhancer, the results were subjected to Bonferroni's correction. Enhancer-gene pairs that survived the eQTL test were considered to have causal regulation.
Computational analysis of enhancer 9
We obtained the raw observation/expectation ratio (O/E ratio) representing the interaction level of distant genomic loci from GEO: GSE63525 (Rao et al., 2014) . The raw O/E ratio was normalized according to the ''readme'' description file in the dataset. We then calculated the median O/E ratio of seven human cell lines of different tissue origins as the final interaction level, as presented in Figure 6C . All the ENCODE ChIP-seq bigwig files (including NF-kB ChIP-seq data) were obtained from the ENCODE data portal. The ChIP-seq signal intensities were extracted from bigwig files, and their mean values were used to measure the NF-kB binding affinity on the enhancer 9 or PD-L1 promoter.
CRISPR/Cas9 genetic perturbation of enhancer 9
The single-guide RNA (sgRNA) sequences were designed using Cas-Designer (http://www.rgenome.net/cas-designer/) within 400 bp sequences flanking the enhancer region (chr9:5580709-5581016). Three gRNAs on either side of the enhancer were selected from the results, generating 9 (3 3 3) possible combinations of sgRNA pairs ( Figure S6B ). The upstream and downstream sgRNA sequences were synthesized and cloned into two CRISPR/Cas9 plasmids (Addgene: 48138 and Addgene: 64324) that respectively express GFP and mCherry as reporters. The sgRNA sequences were validated by Sanger sequencing after plasmid construction. The plasmids with upstream and downstream sgRNAs were mixed and then transfected using lipofectamine 3000 into the human embryonic kidney (HEK) 293T cell line grown in Dulbecco's modification of Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) at 37 C and 5% CO 2 . Three independent transfections were carried out for each pair of sgRNAs. Genetic perturbation efficiency was examined using polymerase chain reaction (PCR) six days after transfection. According to their efficiency, we chose sgRNA-L2 and sgRNA-R3 to generate the enhancer 9 homozygous deletion cell line. To obtain a constant cas9 expression cell line, we first packaged the cas9 plasmid (Addgene: 73310) into lentivirus in the HEK293FT cell line (grown in DMEM with 10% FBS), and then infected the human lung cancer cell line A549 (grown in RPMI-1640 with 10% FBS) by the lentivirus. After one week of blasticidin (25 mg/ml) selection, the A549-cas9 cell line was established. On day 0, 500 ng plasmids with sgRNAs or scramble controls were electroporated into A549-cas9 cell line using 100 ml tips at 1230V with 30ms width and 2 pulses (Neon Transfection System, Life Technologies). After three days of puromycin (4 mg/ml) selection, single cells were seeded into 96-well plates. During colony expansion, genotyping was carried out using KAPA Mouse Genotyping Kit (KAPA Biosystems) to screen single-cell clones with the deletion of enhancer 9. We obtained a homozygous enhancer 9 deletion cell line and confirmed the deletion region by Sanger sequencing. The mRNA and protein levels of PD-L1 expression after enhancer 9 deletion were measured by quantitative reversetranscriptase PCR (qRT-PCR) and western-blot assay, respectively. One day after cell seeding, IFN-g was added to the medium at the final concentration of 1 ng/ml. The expression level of PD-L1 was quantitated three days later. For mRNA expression level, RNA extraction was performed with RNeasy Plus Mini Kit (QIAGEN). The high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific) was used to reverse-transcribe 1 mg total RNA into cDNA. The SYBR select master mix (Thermo Fisher Scientific) and the Mastercycler RealPlex4 (Eppendorf) were used to perform qRT-PCR, which used the following primer sequences. For ACTB, the primer sequences were ATTGGCAATGAGCGGTTC/ CGTGGATGCCACAGGACT, and for PD-L1, the primer sequences were GCATTTACTGTCACGGTTCC/ TGCTGAACCTTCAGGTCTTC. For protein expression level, whole-cell lysates were extracted with RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, protease, and phosphatase inhibitor cocktails) and measured concentration using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). For each sample, 30 mg total protein was loaded into 4%-12% SDS-PAGE, transferred to a polyvinylidene fluoride membrane, and depicted with Amersham ECL Western Blotting Detection Reagents (GE Healthcare Life Sciences). The following antibodies were used: PD-L1 (1:1000, Cell Signaling Technology, 13684T), ACTB (1:30,000, Sigma, A3854).
QUANTIFICATION AND STATISTICAL ANALYSIS
The analyses were based on 8928 tumor samples, except for the clustering analysis, which excluded 599 samples with a low read coverage, and the survival analysis, which excluded 8 cancer types with insufficient patient survival data. The definitions of significance for the various statistical tests are described and referenced in the respective Method Details sections.
DATA AND SOFTWARE AVAILABILITY
The raw data, processed data, and clinical data can be found at the legacy archive of the GDC (https://portal.gdc.cancer.gov/ legacy-archive/search/f) and the PancanAtlas publication page (https://gdc.cancer.gov/about-data/publications/pancanatlas). The mutation data can be found here (https://gdc.cancer.gov/about-data/publications/mc3-2017). TCGA data can also be explored through the Broad Institute FireBrowse portal (http://gdac.broadinstitute.org) and the Memorial Sloan Kettering Cancer Center cBioPortal (http://www.cbioportal.org). Details for software availability are in the Key Resources Table. e5 Cell 
